Patient characteristics
| Characteristics . | All patients (n = 190) . |
|---|---|
| Age, median (range), y | 64 (15-81) |
| Men, n (%) | 118 (62%) |
| Hemopathy and hemopathy histological subtype, n (%) | |
| DLBCL | 138 (73%) |
| DLBCL NOS | 129 (68%) |
| PMBL | 4 (2%) |
| PCNSL | 5 (3%) |
| ALL | 17 (9%) |
| MCL | 13 (7%) |
| FL | 12 (6%) |
| MM | 10 (5%) |
| Type of CAR T cells, n (%) | |
| Axicabtagene ciloleucel | 115 (61%) |
| Tisagenlecleucel | 38 (20%) |
| Brexucabtagene autoleucel | 27 (14%) |
| Idecabtagene vicleucel | 10 (5%) |
| Number of prior lines | |
| Median (range) | 2 (1-7) |
| One prior line, n (%) | 19 (10%) |
| ≥2 prior lines, n (%) | 181 (90%) |
| Toxicities, n (%) | |
| CRS | 165/190 (87%) |
| CRS grade 3+ | 8/190 (4%) |
| ICANS | 91/190 (48%) |
| ICANS grade 3+ | 33/190 (17%) |
| ICU transfer | 46/190 (24%) |
| Characteristics . | All patients (n = 190) . |
|---|---|
| Age, median (range), y | 64 (15-81) |
| Men, n (%) | 118 (62%) |
| Hemopathy and hemopathy histological subtype, n (%) | |
| DLBCL | 138 (73%) |
| DLBCL NOS | 129 (68%) |
| PMBL | 4 (2%) |
| PCNSL | 5 (3%) |
| ALL | 17 (9%) |
| MCL | 13 (7%) |
| FL | 12 (6%) |
| MM | 10 (5%) |
| Type of CAR T cells, n (%) | |
| Axicabtagene ciloleucel | 115 (61%) |
| Tisagenlecleucel | 38 (20%) |
| Brexucabtagene autoleucel | 27 (14%) |
| Idecabtagene vicleucel | 10 (5%) |
| Number of prior lines | |
| Median (range) | 2 (1-7) |
| One prior line, n (%) | 19 (10%) |
| ≥2 prior lines, n (%) | 181 (90%) |
| Toxicities, n (%) | |
| CRS | 165/190 (87%) |
| CRS grade 3+ | 8/190 (4%) |
| ICANS | 91/190 (48%) |
| ICANS grade 3+ | 33/190 (17%) |
| ICU transfer | 46/190 (24%) |
ALL, Acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, Follicular lymphoma; MCL, Mantel cell lymphoma; MM, Multiple myeloma; NOS, not otherwise specified; PMBL, Primary mediastinal B-cell lymphoma